Update Hormonersatz: Bioidentische Hormongaben sind risikoarm

Alexander Römmler

doi:10.1055/s-2007-965452

Zeitschrift für Orthomolekulare Medizin, Table of Contents

Zeitschrift für Orthomolekulare Medizin 2007; 5(2): 16-21
DOI: 10.1055/s-2007-965452

Anti-Aging

Update Hormonersatz: Bioidentische Hormongaben sind risikoarm

Alexander Römmler

Abstract

Zusammenfassung

Die herkömmliche Hormonersatzherapie (HRT) aus oralen Östrogenen und synthetischen Progestagenen ist kurz- und langfristig risikobehaftet. Zur Risikoreduktion von Hormongaben sind vor allem die Wiederherstellung „natürlicher“ Hormonspiegel anzustreben. Dies gelingt durch die human-physiologischen Hormone 17β-Östradiol und Progesteron sowie eine jeweils geeignete Darreichung. Ein solcher „bioidentischer“ Hormonersatz ist an den genitalen und extragenitalen Zielorganen nebenwirkungsarm und wirkt sich günstig auf die Gesunderhaltung und Alterungsprävention aus.

Schlüsselwörter

Hormonersatztherapie - Prävention - Östradiol - Progesteron - bioidentisch

Full Text

References

Literatur

1 Bakken K, Alsaker E, Eggen A E, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer Study. Int J Cancer. 2004; 112 (1) 130-134
2 Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362 (9382) 419-427
3 Beral V, Bull D, Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365 (9470) 1543-1551
4 Brincat M P. Hormone replacement therapy and the skin. Maturitas. 2000; 35 (2) 107-117
5 Campagnoli C, Clavel-Chapelon F, Kaaks R. et al. . Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005; 96 (2) 95-108
6 Canonico M, Straczek C, Oger E. et al. . Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings. Maturitas. 2006; 54 (4) 372-379
7 Chen W Y, Manson J E, Hankinson S E. et al. . Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006; 166 (9) 1027-1032
8 Clavel-Chapelon F, Fournier A. E3 N-EPIC cohort Update. Abstracts, 11th World Congress on the Menopause. Buenos Aires; Oct./2005 Buenos Aires
9 Csizmadi I, Collet J P, Benedetti A. et al. . The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. Br J Cancer. 2004; 90 (1) 76-81
10 De Lignieres B, Dennerstein L, Backstrom T .. Influence of route of progesterone metabolism. Maturitas. 1995; 21 251-257
11 De Lignieres B, de Vathaire F, Fournier S. et al. . Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 2002; 5 (4) 332-340
12 Den Tonkelaar I, Oddens B J. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol. 2000; 95 (4) 507-512
13 Dennison E M, Arden N K, Kellingray S. et al. . Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study. Br J Rheumatol. 1998; 37 (11) 1198-1202
14 Dupont A, Dupont P, Cusan L. et al. . Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas. 1991; 13 (4) 297-311
15 Fabre A, Fournier A, Mesrine S. et al. . Oral progestagens before menopause and breast cancer risk. Br J Cancer. 2007; 96 (5) 841-844
16 Foidart J M, Colin C, Denoo X. et al. . Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998; 69 (5) 963-969
17 Fournier A, Berrino F, Riboli E. et al. . Breast cancer risk in relation to different types of hormone replacement therapy in the E3 N-EPIC cohort. Int J Cancer. 2005; 114 (3) 448-454
18 Grodstein F, Lifford K, Resnick N M, Curhan G C. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol. 2004; 103 (2) 254-260
19 Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006 Jan; 15 (1) 35-44
20 Harvey P J, Morris B L, Miller J A, Floras J S. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women. Hypertension. 2005; 45 (3) 399-405
21 Hendrix S L, Cochrane B B, Nygaard I E. et al. . Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005; 293 (8) 935-948
22 Ho S M. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003; 1 (1) 73-81
23 Huber J C. Hormonveränderungen im Alter: Genitale und extragenitale Auswirkungen. Gynäkologe. 1996; 29 726-734
24 Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002; 13 (6) 583-590
25 Kovari E, Gold G, Herrmann F R. et al. . Cortical microinfarcts and demyelination significantly affect cognition in brain aging. Stroke. 2004; 35 (2) 410-414
26 Lauritzen C. Die präventive Estrogen-Gestagen-Langzeitsubstitution. Frauenarzt. 2001; 42 (11) 1230-1267
27 Le Gal G, Gourlet V, Hogrel P. et al. . Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis. 2003; 166 (1) 163-170
28 Leake R. Contents of HRT and mechanisms of action. J Epidemiol Biostat. 1999; 4 (3) 129-133
29 Leo J C, Wang S M, Guo C H. et al. . Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int J Cancer. 2005; 117 (4) 561-568
30 Micheli A, Muti P, Secreto G. et al. . Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004; 112 (2) 312-318
31 Mosekilde L, Beck-Nielsen H, Sorensen O H. et al. . Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas. 2000; 36 (3) 181-193
32 Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Altern Med Rev. 2006 Sept; 11 (3) 208-223
33 Nelson H D, Humphrey L L, Nygren P. et al. . Postmenopausal hormone replacement therapy: Scientific review. JAMA. 2002; 288 (7) 872-881
34 Oelkers W K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996; 61 (4) 166-171
35 O'Sullivan A J, Crampton L J, Freund J, Ho K KY. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest. 1998; 102 1035-1040
36 Ohlinger R, Klein G M, Köhler G. et al. . Altersverteilung bei Patientinnen mit Mammatumoren in Abhängigkeit vom histologischen Befund. Gyn. 2006; 11 110-116
37 PEPI-Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996; 275 (5) 370-375
38 Plu-Bureau G, Le M G, Thalabard J C. et al. . Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev. 1999; 23 (4) 290-296
39 Rabe T, Geisthövel F, Hadji P. et al. . Hormonersatztherapie - Nutzen und Risiken. J Reproduktionsmed Endokrinol. 2006; 3 (3) 155-165
40 Raine-Fenning N J, Brincat M P, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am J Clin Dermatol. 2003; 4 (6) 371-378
41 Ridker P M, Rifai N, Rose L. et al. . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347 (20) 1557-1565
42 Römmler A. Paradigmenwechsel bei der Substitution mit Östrogenen. ZS Orthomol Med. 2003; 3 13-17
43 Römmler A. Neubewertung der HRT: Orale versus transdermale Östrogene sowie Progestagene versus Progesteron - Wege zur Risikoreduktion. Wolf A, Römmler A, Moltz L, Klentze M Anti Aging Medizin 2003. Berlin; Congress Compact Verlag 2004: 168-194
44 Römmler A. Die Wahrheit über Hormone. München; Südwest 2006
45 Römmler A. Endokrinologische Aspekte der Anti-Aging-Medizin. CME Praktische Fortbildung Gynäkologie, Geburtsmedizin, Gynäkologische Endokrinologie. 2006; 3 18-34
46 Römmler A. Wege zur risikoarmen HRT: Bioidentischer Hormonersatz. J Preventive Medicine. 2007;
47 Rossouw J E, Anderson G L, Prentice R L. et al. . Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288 (3) 321-333
48 Rylance P B, Brincat M, Lafferty K. et al. . Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed). 1985; 290 (6461) 13-14
49 Salpeter S R, Walsh J M, Greyber E. et al. . Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004 Jul; 19 (7) 791-804
50 Scarabin P Y, Oger E, Plu-Bureau G. Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362 (9382) 428-432
51 Scarabin P Y. et al. .Abstracts, 11th World Congress on the Menopause. Buenos Aires; Oct./2005
52 Schuback B. Die ältere Patientin im Brennpunkt der gynäkologischen Onkologie - demografische Entwicklung. Gyn. 2006; 11 451-455
53 Schumacher M, Guennoun R, Robert F. et al. . Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res. 2004; 14 Suppl A S18-S33
54 Stahlberg C, Pedersen A T, Lynge E. et al. . Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004; 109 (5) 721-727
55 Stefanick M L, Anderson G L, Margolis K L. et al. . WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006; 295 (14) 1647-1657
56 Stephenson K, Price C, Kurdowska A. et al. . Progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. Blood. 2004; 104 116
57 Straczek C, Oger E, Yon de Jonage-Canonico M B. et al. . Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112 (22) 3495-3500
58 Tollan A, Oian P, Kjeldsen S E. et al. . Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men. Gynecol Obstet Invest. 1993; 36 (4) 234-238
59 Tsuda K, Kinoshita Y, Nishio I. Synergistic role of progesterone and nitric oxide in the regulation of membrane fluidity of erythrocytes in humans: an electron paramagnetic resonance investigation. Am J Hypertens. 2002; 15 (8) 702-708
60 Vassilev V, Pretto C M, Cornet P B. et al. . Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo. J. Clin Endocrinol Metab. 2005; 90 (10) 5848-5857
61 Von Muhlen D, Morton D, Von Muhlen C A, Barrett-Connor E. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. J Womens Health Gend Based Med. 2002; 11 (6) 511-518
62 Vongpatanasin W, Tuncel M, Wang Z. et al. . Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol. 2003; 41 (8) 1358-1363
63 Weiderpass E, Adami H O, Baron J A. et al. . Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999; 91 (13) 1131-1137
64 Wolf A S. Progestagene sind nicht Progesteron. Römmler A, Wolf AS. Anti-Aging Sprechstunde, Teil 1: Leitfaden für Einsteiger. Berlin; Congress Compact Verlag 2002: 95-102

Privatdozent Dr. med. Alexander Römmler

Gynäkologische Praxisklinik, Hormonzentrum München

Westendstr. 193 - 195

80686 München

URL: http://www.hormonzentrum.de

Supplementary Material

Literaturverzeichnis als PDF